These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7249790)

  • 1. Therapeutic activity of pretazettine on Ehrlich ascites carcinoma: adjuvant effect on standard drugs in ABC regimen.
    Furusawa E; Lum MK; Furusawa S
    Chemotherapy; 1981; 27(4):277-86. PubMed ID: 7249790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination chemotherapy of Rauscher leukemia and ascites tumors by narcissus alkaloid with standard drugs and effect on cellular immunity.
    Furusawa E; Suzuki N; Furusawa S; Lee JY
    Proc Soc Exp Biol Med; 1975 Jul; 149(3):771-8. PubMed ID: 49897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potentials of pretazettine, standard anticancer drugs, and combinations on subcutaneously implanted Lewis lung carcinoma.
    Furusawa E; Furusawa S
    Chemotherapy; 1986; 32(6):521-9. PubMed ID: 3802955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic activity of pretazettine, standard drugs, and the combinations on intraperitoneally implanted Lewis lung carcinoma in mice.
    Furusawa E; Furusawa E; Sokugawa L
    Chemotherapy; 1983; 29(4):294-302. PubMed ID: 6872620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suramin enhancement of the chemotherapeutic actions of cyclophosphamide or adriamycin of intramuscularly-implanted Ehrlich carcinoma.
    Osswald H; Youssef M
    Cancer Lett; 1979 May; 6(6):337-43. PubMed ID: 455271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pretazettine and viva-natural, a dietary seaweed extract, on spontaneous AKR leukemia in comparison with standard drugs.
    Furusawa E; Furusawa S
    Oncology; 1988; 45(3):180-6. PubMed ID: 3368194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic activity of pretazettine on Lewis lung carcinoma.
    Furusawa E; Lockwood RH
    Proc West Pharmacol Soc; 1981; 24():45-7. PubMed ID: 7255485
    [No Abstract]   [Full Text] [Related]  

  • 8. Development of resistance to adriamycin (NSC-123127) in Ehrlich ascites tumor in vivo.
    Danø K
    Cancer Chemother Rep; 1972 Jun; 56(3):321-6. PubMed ID: 19051490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct antitumor effect of cepharanthin and combined effect with adriamycin against Ehrlich ascites tumor in mice.
    Asaumi J; Nishikawa K; Matsuoka H; Iwata M; Kawasaki S; Hiraki Y; Nishijima K
    Anticancer Res; 1995; 15(1):67-70. PubMed ID: 7733643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic activity of pretazettine on Rauscher leukemia: combination of antiviral activity and cellular protein inhibition.
    Furusawa E; Furusawa S; Lee JY; Patanavanich S
    Chemotherapy; 1978; 24(4):259-66. PubMed ID: 648237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chloroaceto hydroxamic acid as antitumor agent against Ehrlich ascites carcinoma in mice.
    Sur P; Bag SP; Sur B; Khanam JA
    Neoplasma; 1997; 44(3):197-201. PubMed ID: 9372863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of N-(o-methoxyphenyl)-maleimide on 5-fluorouracil cytotoxicity in Ehrlich (ascites) carcinoma.
    Ambaye RY; Indap MA
    Cancer Lett; 1991 Apr; 57(1):21-6. PubMed ID: 1902758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Inhibitory action of retinoic acid and N-(4-carboxyphenyl)-retinamide on the biosynthesis of DNA, RNA and protein in Ehrlich ascites carcinoma].
    Song ZP; Han R
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1984 Dec; 6(6):418-20. PubMed ID: 6242543
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of anethole treatment on the tumour induced by Ehrlich ascites carcinoma cells in paw of Swiss albino mice.
    al-Harbi MM; Qureshi S; Raza M; Ahmed MM; Giangreco AB; Shah AH
    Eur J Cancer Prev; 1995 Aug; 4(4):307-18. PubMed ID: 7549823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination chemotherapy for bronchogenic carcinoma with doxorubicin, BCNU, and cyclophosphamide (ABC): a pilot study of the Southeastern Cancer Study Group.
    Denes AE; Presant CA; Bartolucci A
    Cancer Treat Rep; 1982 Jan; 66(1):199-200. PubMed ID: 7053258
    [No Abstract]   [Full Text] [Related]  

  • 16. Polychemotherapy in ovarian cancer: treatment with Adriamycin, BCNU and cyclophosphamide vs. Adriamycin and cyclophosphamide.
    Mazzei T; Bonazza M; Amunni G; Scarselli G; Branconi F; Massi GB
    Chemioterapia; 1984 Feb; 3(1):10-5. PubMed ID: 6535650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic activity of pretazettine, a narcissus alkaloid on Rauscher leukemia: comparison with tazettine and streptonigrin.
    Furusawa E; Furusawa S; Lee JY; Patanavanich S
    Proc Soc Exp Biol Med; 1976 Jun; 152(2):186-91. PubMed ID: 935182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic activity of pretazettine on Rauscher leukemia: comparison with the related Amaryllidaceae alkaloids.
    Furusawa E; Irie H; Combs D; Wildman WC
    Chemotherapy; 1980; 26(1):36-45. PubMed ID: 7353439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron N-(2-hydroxy acetophenone) glycinate (FeNG), a non-toxic glutathione depletor circumvents doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo.
    Ganguly A; Chakraborty P; Banerjee K; Chatterjee S; Basu S; Sarkar A; Chatterjee M; Choudhuri SK
    Biometals; 2012 Feb; 25(1):149-63. PubMed ID: 21915630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic activity of pretazettine, a narcissus alkaloid, on spontaneous AKR leukemia.
    Furusawa E; Lockwood RH; Furusawa S; Lum MK; Lee JY
    Chemotherapy; 1979; 25(5):308-15. PubMed ID: 225136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.